MedTrace Logo

Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease

NCT06053164 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-06

No results posted yet for this study

Summary

The investigators plan to conduct a study to find out if giving portable oxygen therapy (during physical activity) to patients with interstitial lung disease will improve quality of life, exercise tolerance, shortness of breath, and blood vessel function. Oxygen will be provided for a period of 8 weeks. Additionally, the investigators plan to investigate if it is helpful to deliver individualized support when providing oxygen therapy, through check-in phone calls with a respiratory therapist and by providing additional educational material.

Conditions

  • Fibrotic Interstitial Lung Disease

Interventions

DRUG

Exertional Oxygen

Use of a portable oxygen concentrator for exertional activities lasting \>2 minutes

BEHAVIORAL

Education and Support

Participants will receive disease-specific educational material (Living Well with Pulmonary Fibrosis: Oxygen), and will have scheduled phone appointments with a certified respiratory educator after 1, 3, and 5 weeks of oxygen therapy in order to address individual barriers to oxygen use and facilitate the optimal use of portable oxygen.

Sponsors & Collaborators

  • Alberta Boehringer Ingelheim Collaboration

    collaborator UNKNOWN

  • University of Alberta

    lead OTHER

Principal Investigators

  • Mike Stickland · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2026-09-01
Completion
2026-09-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06053164 on ClinicalTrials.gov